386 Complete/near-complete itch response observed in adult and adolescent patients with moderate-to-severe atopic dermatitis initiating dupilumab treatment in real-world practice

被引：0
|
作者：
Bhatia, Neal [1 ]
Lynde, Charles W. [2 ,3 ]
Fonacier, Luz [4 ,5 ]
Tian, Tingting [6 ]
Bosman, Kwinten [7 ]
Korotzer, Andrew [6 ]
机构：
[1] Therapeut Clin Res, San Diego, CA USA
[2] Univ Toronto, Markham, ON, Canada
[3] Lynderm Res, Markham, ON, Canada
[4] New York Univ, Langone Hosp Long Isl, Mineola, NY USA
[5] New York Univ, Long Isl Sch Med, Mineola, NY USA
[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[7] Sanofi, Amsterdam, Netherlands
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
real-world; registry; dupilumab; pruritus;
D O I：
10.1093/bjd/ljad162.013
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
386
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice
    Hagino, Teppei
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    ANNALS OF DERMATOLOGY, 2025, 37 (02) : 86 - 95
  • [32] Effectiveness and safety of dupilumab in moderate-to-severe atopic dermatitis patients with chronic renal insufficiency: a real-world retrospective study in China
    Peng, Cong
    Cao, Qiaozhi
    Xiong, Feng
    Xu, Hui
    Li, Jie
    MEDCOMM, 2024, 5 (10):
  • [33] Coexisting Allergic Rhinitis In Patients With Moderate-To-Severe Asthma Initiating Dupilumab In Real-World Clinical Practice: The RAPID Registry Study
    Peters, Anju
    Cote, Andreanne
    Munoz, Xavier
    Xia, Changming
    Nash, Scott
    Hardin, Megan
    De Prado Gomez, Lucia
    Sacks, Harry
    Jacob-Nara, Juby
    Deniz, Yamo
    Rowe, Paul
    Soler, Xavier
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB96 - AB96
  • [34] Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre
    Kreeshan, Firas Constantin
    Al-Janabi, Ali
    Warren, Richard Bruce
    Hunter, Hamish John Alexander
    DERMATOLOGY AND THERAPY, 2021, 11 (01) : 149 - 160
  • [35] Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre
    Firas Constantin Kreeshan
    Ali Al-Janabi
    Richard Bruce Warren
    Hamish John Alexander Hunter
    Dermatology and Therapy, 2021, 11 : 149 - 160
  • [36] Real Clinical Practice Data of Monthly Dupilumab Therapy in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Clinical Efficacy and Predictive Markers for a Favorable Clinical Response
    Lee, Youngsoo
    Kim, Myoung-Eun
    Nahm, Dong-Ho
    ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2021, 13 (05) : 733 - 745
  • [37] Real-world effectiveness and safety of dupilumab for the treatment of moderate to severe atopic dermatitis in Indian patients: A multi centric retrospective study
    Dhar, Sandipan
    De, Abhishek
    Srinivas, Sahana M.
    INDIAN JOURNAL OF DERMATOLOGY, 2021, 66 (03) : 297 - 301
  • [38] The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan
    Hagino, Teppei
    Saeki, Hidehisa
    Kanda, Naoko
    JOURNAL OF DERMATOLOGY, 2022, 49 (11): : 1158 - 1167
  • [39] Dupilumab treatment significantly improves skin barrier function in adult and adolescent patients with moderate to severe atopic dermatitis
    Berdyshev, Evgeny
    Goleva, Elena
    Bissonnette, Robert
    Bronova, Irina
    Bronoff, Anna Sofia
    Richers, Brittany
    Garcia, Shannon
    Gama, Marco Ramirez
    Taylor, Patricia
    Bologna, Gabriel
    Agueusop, Inoncent
    Boguniewicz, Mark
    Harel, Sivan
    Levit, Noah
    Rossi, Ana
    Zhang, Annie
    Leung, Donald
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB10 - AB10
  • [40] Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan
    Hagino, Teppei
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    JOURNAL OF DERMATOLOGY, 2023, 50 (07): : 869 - 879
12345